Project

Protocol SAKK 11/16: Personalized and cell-based anti-tumor immunization MVX-ONCO-1 in advanced head and neck squamous cell carcinoma. A single arm, open label, multicenter phase II trial

Completed - recruitment closed · 2020 until 2023

Rordorf Tamara